VI Partners related stories
All articles and analysis
Oculis locks in $57m Series COculis, a developer of ophthalmic treatments, has raised $57 million in Series C financing.
iOnctura picks up Series AiOnctura B.V., a Swiss clinical stage biopharmaceutical company, has raised 15 million euros in Series A financing.
VC-backed JenaVale hires two VPsJenaValve Technology Inc, a maker of transcatheter aortic valve replacement systems, has named Dr. Vinny Podichetty as vice president of clinical affairs and Jeff Thiel as vice president of operations. The appointments became effective immediately. JenaValve’s backers include Atlas Venture, Edmond de Rothschild Investment Partners, Gimv, Legend Capital, NeoMed Management, Omega Funds, RMM, Sunstone Capital, Valiance and VI Partners.
- Nexthink collects $85 mln
Nexthink, a provider of digital employee experience management software for enterprises, has secured $85 million in funding. Index Ventures led the round with participation from other investors that included Highland Europe, Forestay Capital, VI Partners, Auriga Partners, Galéo Capital and TOP Funds.
- European medical device company Xeltis scores $52 mln Series C
Xeltis, a European medical device company, has closed $52 million in Series C financing. The investors included Ysios Capital, Kurma Partners and VI Partners.
- VC-backed JenaValve beefs up Munich team with new hire
JenaValve Technology Inc, a maker of transcatheter aortic valve replacement systems, has named Pieter Van den Steen as chief commercial officer and general manager of the company's Munich office. Previously, Van den Steen worked at Boston Scientific. JenaValve's backers included Atlas Venture, Edmond de Rothschild Investment Partners, Gimv, Legend Capital, NeoMed Management, Omega Funds, RMM, Sunstone Capital, Valiance and VI Partners.
- Sequana Medical raises $9.3 mln
Sequana Medical AG said Friday that it raised CHF 9 million (US$9.3 million) in a Series C extension round. Existing investors including NeoMed Management AS, VI Partners AG, Biomed Invest AG, Capricorn Health-tech Fund, Entrepreneurs Fund and Life Science Partners participated for a total of CHF 5.3M, with a further CHF 3.7M raised from new investors including Salus Partners SA and Quest for Growth NV. Sequana Medical, of Zurich, is a medical device company.
- CeQur SA raises $100 mln
CeQur SA said Tuesday it raised a $100 million Series C financing round led by Woodford Investment Management LLP and Arthurian Life Sciences. Existing investors including Endeavour Vision, Schroder & Co. Banque SA, and VI Partners also participated in the round. Lucerne, Switzerland-based CeQur develops and commercializes simple-to-use insulin delivery devices. Peel Hunt LLP acted as financial adviser and placement agent to CeQur SA.
- Swiss biotech company Kuros grabs funding
Swiss biotech company Kuros Biosurgery AG has raised CHF15M (approximately over $15.35 million) in funding. LifeCare Partners and LSP Life Sciences Partners led the round with participation from other investors that included Omega Funds, VI Partners (via Venture Incubator) and The Swiss Helvetia Fund Inc. In addition to the funding, Dr. Gerhard Ries, managing partner of LifeCare Partners, Dr. Jörg Neermann, a partner at LSP and Dominik Ellenrieder have been added to the Kuros board.
- JenaValve scores $26.5 mln Series C
JenaValve Technology Inc, a maker of transcatheter aortic valve repair solutions, has closed $26.5 million in Series C funding. RMM and Valiance led the round with participation from other investors that included Atlas Venture, Edmond de Rothschild Investment Partners, Gimv, Legend Capital, NeoMed Management and VI Partners.